Publication overview

A Comprehensive Overview of the Latest Publications

Publications with contributions From members of NSGO

Since its inception in 1993, NSGO-CTU has been actively involved in conducting clinical trials and publishing research papers in gynecologic oncology. Former and current members, as well as principal investigators (PIs), have contributed significantly to the field, with over 150 publications to their credit.

Features in: Elsevier, Wiley, Springer Nature, American Society of Clinical Oncology (ASCO), Gynecologic Oncology, International Journal of Gynecological Cancer, Cancer Research UK, Journal of Clinical Oncology (JCO), BMC Cancer, Obstetrics & Gynecology and more.

Cervical cancer

Publications & Consensus statements

publications

Consensus statements

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma

Hiroyuki Fujiwara 1, Harushige Yokota, Bradley Monk, Isabelle Treilleux, Mojgan Devouassoux-Shisheboran, Alison Davis, Jae-Weon Kim, Sven Mahner, Michael Stany, Sandro Pignata, Isabelle Ray-Coquard, Keiichi Fujiwara

https://pubmed.ncbi.nlm.nih.gov/253
41589/

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix.

Kosei Hasegawa 1, Shoji Nagao, Masanori Yasuda, David Millan, Akila N Viswanathan, Rosalind M Glasspool, Mojgan Devouassoux-Shisheboran, Alan Covens, Domenica Lorusso, Christian Kurzeder, Jae-Weon Kim, Laurence Gladieff, Jane Bryce, Michael Friedlander, Keiichi Fujiwara

https://pubmed.ncbi.nlm.nih.gov/253
41588/

Practice patterns of radiotherapy in cervical cancer among member groups of the

Gynecologic Cancer Intergroup (GCIG).

D. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A. Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble. 

Int. J. of Radiation OncologyBiologyPhysics, 2007; 68: 485-490

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma. Hiroyuki Fujiwara 1Harushige YokotaBradley MonkIsabelle TreilleuxMojgan Devouassoux-ShisheboranAlison DavisJae-Weon KimSven MahnerMichael StanySandro PignataIsabelle Ray-CoquardKeiichi Fujiwara.

https://ijgc.bmj.com/content/24/Sup
p_3/S96

Gynecologic Cancer InterGroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix  Kosei Hasegawa 1Shoji NagaoMasanori YasudaDavid MillanAkila N ViswanathanRosalind M GlasspoolMojgan Devouassoux-ShisheboranAlan CovensDomenica LorussoChristian KurzederJae-Weon KimLaurence GladieffJane BryceMichael FriedlanderKeiichi Fujiwara

Int J Gynecol Cancer . 2014 Nov;24(9 Suppl 3):S90-5.                   

Practice patterns of radiotherapy in cervical cancer among member groups of the Gynecologic Cancer Intergroup (GCIG). D. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A. Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble.

Int. J. of Radiation OncologyBiologyPhysics, 2007; 68: 485-490

Endometrial cancer

Publications & Consensus statements

publications

Consensus statements

Gynecologic Cancer InterGroup (GCIG) consensus review for high-grade undifferentiated sarcomas of the uterus.

Patricia Pautier 1Eun Ji NamDiane M ProvencherAnne L HamiltonGiorgia MangiliNadeem Ahmad SiddiquiAnneke M WestermannNicholas Simon ReedPhilipp HarterIsabelle Ray-Coquard

https://pubmed.ncbi.nlm.nih.gov/25341584/

Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup.

Giorgia Mangili 1, Domenica Lorusso, Jubilee Brown, Jacobus Pfisterer, Leon Massuger, Michelle Vaughan, Hextan Y S Ngan, Francois Golfier, Paradan K Sekharan, Rafael Cortés Charry, Andres Poveda, Jae-Weon Kim, Yang Xiang, Ross Berkowtiz, Michael J Seckl

https://pubmed.ncbi.nlm.nih.gov/25341573/

Gynecologic Cancer InterGroup (GCIG) consensus review for endometrial stromal sarcoma.

Frédéric Amant 1, Anne Floquet, Michael Friedlander, Gunnar Kristensen, Sven Mahner, Eun Ji Nam, Matthew A Powell, Isabelle Ray-Coquard, Nadeem Siddiqui, Peter Sykes, Anneke M Westermann, Beatrice Seddon

https://pubmed.ncbi.nlm.nih.gov/25033257/

Endometrial cancer state of the science meeting

Kitchener HC, Trimble EL; Endometrial Cancer Working Group of the Gynecologic Cancer Intergroup.

Int J Gynecol Cancer. 2009 Jan-Feb;19(1):134-40

Practice patterns of radiotherapy in endometrial cancer among member groups of the

Gynecologic Cancer Intergroup (GCIG)

W. Small, Du Bois, S. Bhatnagar, N. Reed, S. Pignata, R. Pötter, D. M. Randall, M. R. Mirza, E. L. Trimble, K. Gaffney.

Int. J. Gynecol Cancer, 2009; 19: 395-399.

Ovarian Cancer

Publications & Consensus statements

publications

Consensus statements

Clincal research in ovarian cancer: consensus recmomendations from the Gynecologic Cancer InterGroup

Ignace Vergote 1Antonio Gonzalez-Martin 2Domenica Lorusso 3Charlie Gourley 4Mansoor Raza Mirza 5Jean-Emmanuel Kurtz 6Aikou Okamoto 7Kathleen Moore 8Frédéric Kridelka 9Iain McNeish 10Alexander Reuss 11Bénédicte Votan 12Andreas du Bois 13Sven Mahner 14Isabelle Ray-Coquard 15Elise C Kohn 16Jonathan S Berek 17David S P Tan 18Nicoletta Colombo 19Rongyu Zang 20Nicole Concin 21Dearbhaile O’Donnell 22Alejandro Rauh-Hain 23C Simon Herrington 24Christian Marth 25Andres Poveda 26Keiichi Fujiwara 27Gavin C E Stuart 28Amit M Oza 29Michael A Bookman 30participants of the 6th Gynecologic Cancer InterGroup (GCIG) Ovarian Cancer Consensus Conference on Clinical Research

Lancet Oncol. 2022 Aug;2(8):e374-e384.

Nonepithelial ovarian cancer – the current clinical practice in the Nordic countries. Survey from the surgical subcommitte of the Nordic society of gyncological oncology (NSGO)

Cristina Daviu 1Jan Blaakaer 2 Ane Gerda Z Eriksson3 Jørn Herrstedt 4M P Vandborg5Anne Mette Odgaard Rasmussen6 Katrine Fuglsang 7

Acta Oncol. 2022 Aug;61(8):939-945.

Symptom burden and quality of life with chemotherapy for recurrent ovarian cancer: the Gynecologic Cancer InterGrpuå-Symptom Benefit Study

Yeh Chen Lee 1Madeleine T King 2Rachel L O’Connell 3Anne Lanceley 4Florence Joly 5Felix Hilpert 6Alison Davis 7Felicia T Roncolato 8Aikou Okamoto 9Jane Bryce 10Paul Donnellan 11Amit M Oza 12Elisabeth Avall-Lundqvist 13Jonathan S Berek 14Jonathan A Ledermann 15Dominique Berton 16Jalid Sehouli 17Amanda Feeney 18Marie-Christine Kaminsky 19Katrina Diamante 20Martin R Stockler 21Michael L Friedlander 22GCIG Symptom Benefit Group

INT J Gynecol Cancer. 2022 Jun 6;32(6)761-768.

Clinical pathways of recovery after surgery for advanced ovarian/tubal/peritoneal cancer: an NSGO-MaNGO international survey in collaboration with AGO-a focus on surgical aspects

Elisa Piovano 1Annamaria Ferrero 2Paolo Zola 3 4Christian Marth 5Mansoor Raza Mirza 6Kristina Lindemann 7 8

Int J Gynecol Cancer . 2019 Jan;29(1):181-187.

Quality of life in patients with advanced epithelial ovarian cancer (EOC) randomized to maintenance pazopanib or placebo after first-line chemotherapy in the AGO-OVAR 16 trial. Measuring what matters-patient-centered end points in trials of maintenance therapy

M Friedlander 1, J Rau 2, C K Lee 3, W Meier 4, A Lesoin 5, J-W Kim 6, A Poveda 7, M Buck 8, G Scambia 9, M Shimada 10, F Hilpert 11, M T King 12, P Debruyne 13, A Bologna 14, S Malander 15, B J Monk 16, E Petru 17, P Calvert 18, T J Herzog 19, C Barrett 20, A du Bois 21

Ann Oncol . 2018 Mar 1;29(3):737-743.

Measuring what matters MOST: validation of the Measure of Ovarian Symptoms and Treatment, a patient-reported outcome measure of symptom burden and impact of chemotherapy in recurrent ovarian cancer

Madeleine T King 1 2 3, Martin R Stockler 4 5, Rachel L O’Connell 5, Luke Buizen 5, Florence Joly 6 7, Anne Lanceley 8, Felix Hilpert 9 10, Aikou Okamoto 11 12, Eriko Aotani 13 14, Jane Bryce 15 16, Paul Donnellan 17, Amit Oza 18 19, Elisabeth Avall-Lundqvist 20 21 22, Jonathan S Berek 23 24, Jalid Sehouli 10 25, Amanda Feeney 26, Dominique Berton-Rigaud 7 27, Daniel S J Costa 28 29, Michael L Friedlander 4 30, GCIG Symptom Benefit group

Qual Life Res . 2018 Jan;27(1):59-74.

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

M K Wilson 1, E Pujade-Lauraine 2, D Aoki 3, M R Mirza 4, D Lorusso 5, A M Oza 6, A du Bois 7, I Vergote 8, A Reuss 7, M Bacon 9, M Friedlander 1, D Gallardo-Rincon 10, F Joly 2, S-J Chang 11, A M Ferrero 12, R J Edmondson 13, P Wimberger 14, J Maenpaa 4, D Gaffney 15, R Zang 16, A Okamoto 3, G Stuart 17, K Ochiai 3, participants of the Fifth Ovarian Cancer Consensus Conference

Ann Oncol . 2017 Apr 1;28(4):727-732

Gynecologic Cancer InterGroup (GCIG) consensus review for squamous cell carcinoma of the ovary.

Rosalind M Glasspool 1Antonio González MartínDavid MillanDomenica LorussoElisabeth Åvall-LundqvistJean A HurteauAlison DavisFelix HilpertJae-Weon KimJérôme AlexandreJonathan A Ledermann

https://pubmed.ncbi.nlm.nih.gov/25126954/

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)

Philipp Harter 1David GershensonCatherine LhommeFabrice LecuruJonathan LedermannDiane M ProvencherDelia MezzanzanicaMichael QuinnJohanna MaenpaaJae-Weon KimSven MahnerFelix HilpertKlaus BaumannJacobus PfistererAndreas du Bois

https://pubmed.ncbi.nlm.nih.gov/25341581/

Gynecologic Cancer InterGroup (GCIG) consensus review for carcinoid tumors of the ovary.

Nicholas Simon Reed 1Eva Gomez-GarciaDolores Gallardo-RinconBrigitte BarretteKlaus BaumannMichael FriedlanderGanessan KichenadasseJae-Weon KimDomenica LorussoMansoor Raza MirzaIsabelle Ray-Coquard

https://pubmed.ncbi.nlm.nih.gov/25341578/

Gynecologic Cancer InterGroup (GCIG) consensus review: uterine and ovarian leiomyosarcomas.

Martee L Hensley 1, Brigitte A Barrette, Klaus Baumann, David Gaffney, Anne L Hamilton, Jae-Weon Kim, Johanna U Maenpaa, Patricia Pautier, Nadeem Ahmad Siddiqui, Anneke M Westermann, Isabelle Ray-Coquard

https://pubmed.ncbi.nlm.nih.gov/25341583/

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine and ovarian carcinosarcoma.

Dominique Berton-Rigaud 1, Mojgan Devouassoux-Shisheboran, Jonathan A Ledermann, Mario M Leitao, Matthew A Powell, Andres Poveda, Philip Beale, Rosalind M Glasspool, Carien L Creutzberg, Philipp Harter, Jae-Weon Kim, Nicholas Simon Reed, Isabelle Ray-Coquard

https://pubmed.ncbi.nlm.nih.gov/25341582/

Gynecologic Cancer Intergroup (GCIG) consensus review for ovarian germ cell tumors.

Jubilee Brown 1, Michael Friedlander, Floor J Backes, Philipp Harter, Dennis M O’Connor, Thibault de la Motte Rouge, Domenica Lorusso, Johanne Maenpaa, Jae-Weon Kim, Meghan E Tenney, Michael J Seckl

https://pubmed.ncbi.nlm.nih.gov/25341580/

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian sex cord stromal tumors

Isabelle Ray-Coquard 1, Jubilee Brown, Philipp Harter, Diane M Provencher, Peter C Fong, Johanna Maenpaa, Jonathan A Ledermann, Gunter Emons, Dominique Berton Rigaud, Rosalind M Glasspool, Delia Mezzanzanica, Nicoletta Colombo

https://pubmed.ncbi.nlm.nih.gov/25341579/

Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serouscarcinomas.

Charlie Gourley 1, John Farley, Diane M Provencher, Sandro Pignata, Linda Mileshkin, Philipp Harter, Johanna Maenpaa, Jae-Weon Kim, Eric Pujaide-Lauraine, Rosalind M Glasspool, Isabelle Ray-Coquard, David Gershenson

https://pubmed.ncbi.nlm.nih.gov/25341587/

Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the ovary

Aikou Okamoto 1, Rosalind M Glasspool, Seiji Mabuchi, Noriomi Matsumura, Hiroyuki Nomura, Hiroaki Itamochi, Masashi Takano, Tadao Takano, Nobuyuki Susumu, Daisuke Aoki, Ikuo Konishi, Alan Covens, Jonathan Ledermann, Delia Mezzanzanica, Christopher Steer, David Millan, Iain A McNeish, Jacobus Pfisterer, Sokbom Kang, Laurence Gladieff, Jane Bryce, Amit Oza

https://pubmed.ncbi.nlm.nih.gov/25341576/

A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer

Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M.

Ann Oncol. 2013 Apr;24(4):937-43

Clinical trials in recurrent ovarian cancer.

Friedlander M, Trimble E, Tinker A, Alberts D, Avall-Lundqvist E, Brady M, Harter P, Pignata S, Pujade-Lauraine E, Sehouli J, Vergote I, Beale P, Bekkers R, Calvert P, Copeland L, Glasspool R, Gonzalez-Martin A, Katsaros D, Kim JW, Miller B, Provencher D, Rubinstein L, Atri M, Zeimet A, Bacon M, Kitchener H, Stuart GC; Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2011 May;21(4):771-5.

First-Line Therapy in Ovarian Cancer Trials.

Thigpen T, Dubois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W, Kristensen G, Mannel R, Markman M, Pfisterer J, Quinn M, Reed N, Swart AM, Berek J, Colombo N, Freyer G, Gallardo D, Plante M, Poveda A, Rubinstein L, Bacon M, Kitchener H, Stuart GC; on behalf of the Gynecologic Cancer InterGroup.

Int J Gynecol Cancer. 2011 May;21(4):756-762.

Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG).

Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, du Bois A,Kristensen G, Jakobsen A, Sagae S, Greven K, Parmar M, Friedlander M, Cervantes A. Vermorken J.

Int J Gynecol Cancer. 2011 Feb;21(2):419-423

Prognostic nomogram to predict progression-free survival in patients with platinum- sensitive recurrent ovarian cancer.

Lee CK, Simes RJ, Brown C, Lord S, Wagner U, Plante M, Vergote I, Pisano C, Parma G, Burges A, Bourgeois H, Högberg T, Bentley J, Angleitner-Boubenizek L, Ferrero A, Richter B, Hirte H, Gebski V, Pfisterer J, Pujade-Lauraine E, Friedlander M

https://pubmed.ncbi.nlm.nih.gov/21915127/

Early decline in cancer antigen 125 as a surrogate for progression-free survival in recurrent ovarian cancer

Lee CK, Friedlander M, Brown C, Gebski VJ, Georgoulopoulos A, Vergote I, Pignata S, Donadello N, Schmalfeldt B, Delva R, Mirza MR, Sauthier P, Pujade-Lauraine E, Lord SJ, Simes RJ.

J Natl Cancer Inst. 2011 Sep 7;103(17):1338-42.

Carboplatin-paclitaxel-induced leukopenia and neuropathy predict progression-free survival in recurrent ovarian can

Lee CK, Gurney H, Brown C, Sorio R, Donadello N, Tulunay G, Meier W, Bacon M, Maenpaa J,

Petru E, Reed N, Gebski V, Pujade-Lauraine E, Lord S, Simes RJ, Friedlander M.

Br J Cancer. 2011 Jul 26;105(3):360-5.

European Network of Gynaecological Oncological Trial Groups’ Requirements for Trials Between Academic Groups and Pharmaceutical Companies

Vergote I, Pujade-Lauraine E, Pignata S, Kristensen GB, Ledermann J, Casado A, Sehouli J,

Mirza M, Fossati R, Marth C, Creutzberg C, Del Campo J, Siddiqui N, Calvert P, Bamias A,Tulunay G, van der Zee AG, du Bois A; European Network of Gynaecological Oncological Trial Groups

Int J Gynecol Cancer 2010;20: 476-478

Clinical trials in gynecological cancer.

Trimble EL, Davis J, Disaia P, Fujiwara K, Gaffney D, Kristensen G, Ledermann J, Pfisterer J, Quinn M, Reed N, Schoenfeldt M, Thigpen JT; Gynecologic Cancer Intergroup.

Int J Gynecol Cancer. 2007 May-Jun;17(3):547-56

Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.

Rustin GJ, Timmers P, Nelstrop A, Shreeves G, Bentzen SM, Baron B, Piccart J, Bertelsen K, Stuart G, Cassidy J, Eisenhauer E.

J Clin Oncol. 2006 Jan 1;24(1):45-51

Clinical trials in ovarian carcinoma: requirements for standard approaches and regimens.

Thigpen T, Stuart G, du Bois A, Friedlander M, Fujiwara K, Guastalla JP, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Poveda A, Provencher D, Stehman F, Vergote I.

Ann Oncol. 2005 Oct;16 Suppl 8:viii13-viii19

2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference(GCIG OCCC 2004).

duBois A, Quinn M, Thigpen T, Vermorken J, Avall-Lundqvist E, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Neijt JP, Oza A, Ozols R, Parmar M, Pecorelli S, Pfisterer J, Poveda A, Provencher D, Pujade- Lauraine E, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Stuart G, Trimble E, Vasey P, Vergote I, Verheijen R, Wagner U; Gynecologic Cancer Intergroup; AGO-OVAR; ANZGOG; EORTC; GEICO; GINECO; GOG; JGOG; MRC/NCRI; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG; IGCS; Organizational team of the two prior International OCCC.

Ann Oncol. 2005;16 Suppl 8:viii7-viii12.

3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration

Stuart G, Avall-Lundqvist E, du Bois A, Bookman M, Bowtell D, Brady M, Casado A, Cervantes A, Eisenhauer E, Friedlaender M, Fujiwara K, Grenman S, Guastalla JP, Harper P, Hogberg T, Kaye S, Kitchener H, Kristensen G, Mannel R, Meier W, Miller B, Oza A, Ozols R, Parmar M, Pfisterer J, Poveda A, Provencher D, Pujade-Lauraine E, Quinn M, Randall M, Rochon J, Rustin G, Sagae S, Stehman F, Trimble E, Thigpen T, Vasey P, Vergote I, Verheijen R, Vermorken J, Wagner U; NCIC-CTG; NSGO; AGO-OVAR; GOG; ANZGOG; EORTC; GEICO; JGOG; GINECO; MRC/NCRI; SGCTG; RTOG; NCI-US.

Ann Oncol. 2005;16 Suppl 8:viii36-viii38.

History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004

Quinn M, Avall-Lundqvist E, du Bois A, Vermorken J, Parmar M, Pfisterer J, Stuart G, Thigpen T, Neijt J.

Ann Oncol. 2005;16 Suppl 8:viii5-viii6.

The Gynecologic Cancer Intergroup (GCIG): history and current status

Vermorken JB, Avall-Lundqvist E, Pfisterer J, Bacon M; GCIG; AGO-OVAR; ANZGOG; EORTC-GCC; GEICO; GINECO; GOG; JGOG; MRC; NCIC-CTG; NCI-US; NSGO; RTOG; SGCTG.

Ann Oncol. 2005;16 Suppl 8:viii39-viii42

Integration of new or experimental treatment options and new approaches to clinical trials

Quinn M, Pfisterer J, Avall-Lundqvist E, Bookman M, Bowtell D, Casado A, Cervantes A, Grenman S, Harper P, Oza A, Pecorelli S, Pujade-Lauraine E, Trimble E, Vasey P, Wagner U; ANZGOG; AGO-OVAR; NSGO; GOG; EORTC; GEICO; MRC/NCRI; NCIC-CTG; IGCS; GINECO; NCI-US; SGCTG.

Ann Oncol. 2005;16 Suppl 8:viii30-viii35

New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer).

Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, Eisenhauer E, Sagae S, Greven K, Vergote I, Cervantes A, Vermorken J.

J Natl Cancer Inst. 2004 Mar 17;96(6):487-8.

Pognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma.

Vergote I, De Brabanter J, Fyles A, Bertelsen K, Einhorn N, Sevelda P, Gore E, Kaern J, Verrelst H, Sjovall K, Timmerman D, Vandewalle J, Van Gramberen , Trope CG.

Lancet. 2001 Jan 20;357(9251):176-82.

New guidelines to evaluate the response to treatment in solid tumors [ovarian cancer]. Gynecologic Cancer Intergroup.

Vergote I, Rustin GJ, Eisenhauer EA, Kristensen GB, Pujade-Lauraine E, Parmar MK, Friedlander M, Jakobsen A, Vermorken JB.

J Natl Cancer Inst. 2000 Sep 20;92(18):1534-5.

Epithelial ovarian cancer (advanced stage): consensus conference (1998)

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Thigpen JT, Trope C, Tuxen K, Vergote I, Vermorken JB, Willemse PH.

Gynecol Obstet Fertil. 2000 Jul-Aug;28(7-8):576-83.

Advanced epithelial ovarian cancer: 1998 consensus statements

Berek JS, Bertelsen K, du Bois A, Brady MF, Carmichael J, Eisenhauer EA, Gore , Grenman S, Hamilton TC, Hansen SW, Harper PG, Horvath G, Kaye SB, Luck J, Lund B, McGuire WP, Neijt JP, Ozols RF, Parmar MK, Piccart-Gebhart MJ, van Rijswijk R, Rosenberg P, Rustin GJ, Sessa C, Willemse PH, et al.

Ann Oncol. 1999;10 Suppl 1:87-92

Intergroup collaboration in ovarian cancer: a giant step forwar

Piccart MJ, Stuart GC, Cassidy J, Bertelsen K, Parmar MK, Eisenhauer EA, Kaye B, Trope C, Swenerton K, Harper P, Vermorken JB.

Ann Oncol. 1999;10 Suppl 1:83-6.

Advanced epithelial ovarian cancer: 1993 consensus statement Allen DG, Baak J, Belpomme D, Berek JS, Bertelsen K, ten Bokkel Huinink W, van der Burg ME, Calvert AH, Conte PF, Dauplat J, et al

Ann Oncol. 1993;4 Suppl 4:83-8.

Vulva Cancer

Publications & Consensus statements

publications

Consensus statements

Gynecologic Cancer InterGroup (GCIG) consensus review for mullerian adenosarcoma of the female genital tract.

Michael Leonard Friedlander 1Alan CovensRosalind M GlasspoolFelix HilpertGunnar KristensenSanghoon KwonFrederic SelleWilliam SmallEls WitteveenPeter Russell

https://pubmed.ncbi.nlm.nih.gov/25341585/

Gynecologic Cancer InterGroup (GCIG) consensus review for vulvovaginal melanomas.

Mario M Leitao Jr 1Xi ChengAnne L HamiltonNadeem A SiddiquiIna Jurgenliemk-SchulzSven MahnerElisabeth Åvall-LundqvistKidong KimGilles Freyer

https://pubmed.ncbi.nlm.nih.gov/24987924/

Patterns of care for radiotherapy in vulvar cancer: A Gynecologic Cancer Intergroup (GCIG) study.

D. Gaffney, A. Du Bois, K. Narayan, N. Reed, T. Toita, S. Pignata, P. Blake, L. Portelance, A. Sadoyze, R. Pötter, A. Colombo, M. Randall, M. R. Mirza, E. L. Trimble.

Int. J. Gynecol Cancer, 2009; 19: 163-7.

We use cookies to give you the best experience on our website. You can find out more about which cookies we use:

Nødvendige

Required cookies help make the site usable by enabling basic features such as Slide functions, and ensure full access to all pages on our site. The website does not work optimally without these cookies. We have considered these as paid and are therefore stored without prior consent.

Expires
session
Name
PHPSESSID
Data processor
System
Purpose
Bruges til at holde styr op brugrens session
Expires
1 year
Name
wordpress_[hash]
Data processor
System
Purpose
Ved login bruger WordPress wordpress_[hash] cookien til at gemme dine godkendelsesoplysninger.
Expires
1 year
Name
wordpress_logged_in_[hash]
Data processor
System
Purpose
Efter login indstiller WordPress wordpress_logged_in_[hash] cookien, der angiver, hvornår du er logget ind, og hvem du er, til de fleste grænsefladebrug.
Expires
1 year
Name
wp-settings-{time}-[UID]
Data processor
System
Purpose
Dette bruges til at tilpasse din visning af admin interface, og muligvis også hovedwebstedets interface.
Expires
1 year
Name
comment_author_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
1 year
Name
comment_author_email_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
1 year
Name
comment_author_url_{HASH}
Data processor
System
Purpose
Når besøgende kommenterer din blog, får de også gemt cookies på deres computer.
Expires
session
Name
woocommerce_cart_hash
Data processor
System
Purpose
Hjælper WooCommerce med at afgøre, hvornår vognens indhold/data ændres.
Expires
session
Name
woocommerce_items_in_cart
Data processor
System
Purpose
Hjælper WooCommerce med at afgøre, hvornår vognens indhold/data ændres.
Expires
2 dage
Name
wp_woocommerce_session_
Data processor
System
Purpose
Indeholder en unik kode for hver kunde, så den ved, hvor han kan finde vogndataene i databasen for hver kunde.
Expires
session
Name
woocommerce_recently_viewed
Data processor
System
Purpose
Giver widgeten Seneste viste produkter.
Expires
session
Name
store_notice[notice id]
Data processor
System
Purpose
Tillader kunder at afvise butiksmeddelelsen.
Expires
1 year
Name
cookie_settings
Data processor
System
Purpose
Bruges til at angive dine cookieindstillinger.

Privacy Policy for NSGO

NSGO treats personal information and complies with the laws and principles of good data processing practices. Therefore, we have adopted this Privacy Policy, which briefly describes how we treat personal information, so legal and transparent processing is ensured.

We are responsible for processing your personal information:

NSGO is the data controller and you can always contact the organization’s data protection officer:

Mansoor Raza Mirza

Nordic Society of Gynecologic Oncology – Clinical Trial Unit
Copenhagen University Hospital
Department of Oncology, 9431
Blegdamsvej 60
DK-2100 Copenhagen
Office phone: +45 35 45 33 78
fax: +45 3545 2898
Mansoor.Raza.Mirza@regionh.dk.

We treat the following personal information about members:

  • General personal information: For example, contact information such as name, work address, work phone number, private phone number, date of birth, email address, country, work title, date of membership, date of membership termination and cv in relation to membership application. Parts of credit card number via Epay and, if applicable, Bank account number for reimbursement purposes. When applicable, Board Members may be asked to give NSGO copies of other personal documents (for example passport or tax bill) in relation to the Danish Laundering Act.
  • Other information: For example, positions of trust, board membership and other duties in relation to the organization.

We collect personal information from:

Usually we will get the information from you, when you register to become a member of NSGO and when you apply for reimbursements or pay your membership fee

The organization’s legal basis to process personal information:

  • That we as an organization have a (legitimate) interest in processing your information
  • That it is necessary for us to fulfill an agreement with you
  • You have agreed that we can process your information via becoming a member of the

The purpose of processing personal information:

  • That we can run the organization’s activities, including planning, implementing and following up on them
  • To invite to vote for Board and President Elect elections
  • To distribute newsletters
  • To comply with legislation
  • To deliver services, in the form of the possibility to participate in the Annual Meeting, Investigator Meeting and if applicable Strategic Meetings, Board Meetings, Scientific Committee Meetings, Foundation Meetings.
  • To notify members about other Gynecologic Cancer Managing your relationship with the organization
  • To handle your membership rights
  • For you to fulfill your obligations as a member of the organization, including paying the membership fee, etc.
  • Being able to display situation images from a specific event in the organization for instance from NSGO Annual Meetings
  • To maintain historical value data for statistics and the like

Consent:

When you become a member, we have a legal basis to process your personal information for the (legitimate) interest of the organization. However, it may happen that we judge it necessary to obtain your written consent for other purposes. In that case you will have the opportunity to voluntarily agree, and you may withdraw it at any time by notifying us.

Dispatch of your personal information:

We do not disclose information about you to anyone outside the organization without your consent, however, it should be noted, that if you e.g. accept an invitation to a meeting, your personal information might be forwarded to the meeting location or the meeting organizer. Only personal information relevant for the 3rd party will be disclosed in these circumstances.

Storing and deleting your personal information:

For historical reasons and as your details might be saved in old attendance lists, email correspondence and minutes from meetings, we cannot promise that all personal information about you will be deleted, if you terminate your membership.

Your rights:

You have a number of rights via the General Data Protection Regulation (GDPR):

  • The Right to Information (to be informed what information we process about you)
  • The Right to Rectification (to have false information about you corrected)
  • The Right to Restriction of processing (under certain conditions, to have the processing of your data restricted)
  • The Right to Object (to object to your information being used for wrong purposes)

You may make use of your rights by contacting us. If you submit a request to have your personal information corrected or deleted, we will investigate whether the conditions are met and, in that case, make changes or deletions as soon as possible and, if applicable, also notify our data processors to do so.

You can file a complaint with the supervisory authorities – The Danish ‘Datatilsynet’ – About processing your personal information (www.datatilsynet.dk).

Revision of Privacy Policy:

We reserve the right to change the organization’s privacy policy. When we change privacy policy, we also change the date and version number at the bottom of this document. In case of significant changes, you will receive a notification.

The current privacy policy is always available on our website.

Practice Areas

Newsletter

Sign up to our newsletter

Privacy Policy for NSGO-CTU

NSGO-CTU treats personal information and complies with the laws and principles of good data
processing practices. Therefore, we have adopted this Privacy Policy, which briefly describes how we treat personal information, so legal and transparent processing is ensured.

We are responsible for processing your personal information:

NSGO-CTU is the data controller and you can contact the organization’s data protection officer:

Mansoor Raza Mirza

Nordic Society of Gynecologic Oncology – Clinical Trial Unit
Copenhagen University Hospital
Department of Oncology, 9431
Blegdamsvej 60
DK-2100 Copenhagen
Office phone: +45 35 45 33 78
fax: +45 3545 2898
Mansoor.Raza.Mirza@regionh.dk.

We treat the following personal information about personnel participating in NSGO-CTU trials:
• General personal information: For example; contact information such as name, work
address, work phone number, date of birth, email address, country, work title, date of start
of participation and termination in a trial and, if applicable, CV, GCP certificates, records of
training and other qualification data.
• If applicable, financial disclosure forms and/or Bank account number for reimbursement
purposes.

We collect personal information from:
• We will ask you to provide us the information yourself, when you in decide to take part
in NSGO-CTU trials.
The organization’s legal basis to process personal information:
• That we as an organization have a (legitimate) interest in processing your information, for
example to secure your qualifications in handling the care of the participants in a trial.
• That it is necessary for us to fulfill an agreement with your employer
• You have agreed that we can process your information via signing the delegation log.
The purpose of processing personal information:
• The participation of an investigator or of other individuals in a clinical trial which is being
conducted according to the principals governing clinical research as set out in the
Declaration of Helsinki and with the acceptance of all involved Regulatory Health
Authorities and involved Ethical Committees, requires collection, recording, storage,
transfer and/or other use of personal data (personal data processing).
• Communicate regarding studies.
• To handle payments and reimbursements.
• To comply with legislation.
• To deliver services, in the form of the possibility to participate in the Annual Meeting,
Investigator Meeting.
• To be able to give you access to IT systems, databases, eCRFs etc. related to the functioning
of each individual trial.

Consent:
When you decide to take part in a NSGO-CTU trial NSGO-CTU either makes a contract with you or
your employer where terms and conditions are described, or if you put your name on the
Delegation Log of a trial, you agree to the information described in this Privacy Policy.
However, it may happen that we judge it necessary to obtain your written consent for other
purposes. In that case you will have the opportunity to voluntarily agree, and you may withdraw it
at any time by notifying us.
Be aware that there are legal bases for certain forms of processing of your data for the abovementioned purposes and that your consent is the only legal basis for other forms of processing.

Dispatch of your personal information:
Depending on your role in a trial, your personal information might be shared with personnel at
other sites, monitors, group staff in other countries, NSGO-CTU office staff, members of NSGO,
CRO staff, Ethics Committees and Competent Authorities, both in Europe, but also in countries
outside the European Economic Area (for example the US). If your data (personal information) has
been transferred, they will be subject to the data protection legislation of the respective country,
also if a less severe data protection law should exist.
We do not disclose information about you to anyone outside the organization without the above
consent, however, it should be noted, that if you e.g. accept an invitation to a meeting, your
personal information might be forwarded to the meeting location or the meeting organizer. Only
personal information relevant for the 3rd party will be disclosed in these circumstances.
Furthermore, your data can be transmitted to public databases for registration, as well as
publication of a trial and your data can be stored and published in those databases.
Storing and deleting your personal information:
For historical reasons and as your details might be saved in old attendance lists, email
correspondence and minutes from meetings, we cannot promise that all personal information
about you will be deleted, when you end your participation in a study. In general, all information
about a trial is deleted at least 20 years after end of study.

Your rights:
You have a number of rights via the General Data Protection Regulation (GDPR):
• The Right to Information (to be informed what information we process about you)
• The Right of Access (to get a print of the information we process about you)
• The Right to Rectification (to have false information about you corrected)
• The Right to Erasure (to delete information we process about you, however, information
already received cannot be deleted)
• The Right to Restriction of processing (under certain conditions, to have the processing of
your data restricted)
• The Right to Object (to object to your information being used for wrong purposes)

You may make use of your rights by contacting us, however, the legality of the processing carried out
prior to e.g., a withdrawal will not be affected. If you submit a request to have your personal
information corrected or deleted, we will investigate whether the conditions are met and, in that
case, make changes or deletions as soon as possible and, if applicable, also notify our data
processors to do so.

If you do not believe that NSGO-CTU handles your data correctly, you can file a complaint with the
supervisory authorities – The Danish ‘Datatilsynet’ – About processing your personal information
(www.datatilsynet.dk).

Revision of Privacy Policy:
We reserve the right to change the organization’s privacy policy. When we change privacy policy,
we also change the date and version number at the bottom of this document. In case of significant
changes, you will receive a notification.

The current privacy policy for NSGO-CTU is always available on our website.

Practice Areas

Newsletter

Sign up to our newsletter

Found Something Interesting?

Powered By EmbedPress